Recent data from KFF (a nonprofit formerly known as the Kaiser Family Foundation) shows that while monthly premiums are dropping for many stand-alone drug plans, beneficiaries will have fewer options to choose from — and some expensive medications will cost significantly more.

The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under Medicare, including Ozempic and Wegovy

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

The Trump administration is touting $12 billion in federal savings in Medicare’s second year of drug price negotiations.